AVADEL PHARMACEUTICALS PLC — Director's Dealing 2020

Dec 9, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AVADEL PHARMACEUTICALS PLC (AVDL)
CIK: 0001012477
Period of Report: 2020-12-08

Reporting Person: Divis Gregory J (Director, Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-12-08	Stock Option (right to buy)	$6.79	A	500000	Acquired	2030-12-08	ADSs (500000)	Direct

Footnotes

F1: Options become exercisable as to 125,000 ADSs on each of the first four anniversaries after the 12/08/2020 grant date.

F2: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.